

# EC CERTIFICATE

Number: 2110151CE05

## Full Quality Assurance System

**Directive 98/79/EC on In Vitro Diagnostic Medical Devices, Annex IV excluding (4,6)**  
(List A, B and devices for self-testing)

Manufacturer:

**Elitechgroup S.P.A.**

**Corso Svizzera 185**

**10149 Torino**

**Italy**

For the product category(ies)

**Nucleic acid reverse transcription and amplification assays and related components used for the detection and quantification of Hepatitis B and C virus DNA and/or RNA in human plasma and serum**

DEKRA grants the right to use the EC Notified Body Identification Number illustrated below to accompany the CE Marking of Conformity on the products concerned conforming to the required Technical Documentation and corresponding batch release certificate(s) and meeting the provisions of the EC-Directive which apply to them:

# 0344

Documents, that form the basis of this certificate:

**Certification Notice 2110151CN, initially dated 26 February 2008**

DEKRA hereby declares that the above mentioned manufacturer fulfils the relevant provisions of 'Besluit in-vitro diagnostica', the Dutch transposition of the Council Directive 98/79/EC of October 27, 1998 concerning In vitro diagnostic medical devices, including all subsequent amendments. The manufacturer has implemented a quality assurance system for design, manufacture and final inspection for the above mentioned product category in accordance to the provisions of Annex IV of Council Directive 98/79/EC of October 27, 1998 and is subject to periodical surveillance. For placing on the market of List A devices an additional EC design examination certificate according to Annex IV (4) is mandatory.


The necessary information related to the quality assurance system of the manufacturer, including facilities and the reference to the relevant documentation, of the products concerned and the assessments performed, are stated in the Certification Notice which forms an integrative part of this certificate.

This certificate is valid until: 26 May 2025

Issued for the first time: 15 December 2021

Revised: 19 May 2022

DEKRA Certification B.V.



**B.T.M. Holtus**  
Managing Director



**J.A. van Vugt**  
Certification Manager

© Integral publication of this certificate and adjoining reports is allowed

DEKRA Certification B.V. is Notified Body with ID no 0344

DEKRA Certification B.V. Meander 1051, 6825 MJ Arnhem P.O. Box 5185, 6802 ED Arnhem, The Netherlands  
T +31 88 96 83000 F +31 88 96 83100 www.dekra.nl Company registration 09085396



# EC DESIGN-EXAMINATION CERTIFICATE

Number: 2110151DE01

**Directive 98/79/EC on In Vitro Diagnostic Medical Devices, Annex IV (4)**  
(List A)

Manufacturer:

**Elitechgroup S.P.A.**  
Corso Svizzera 185  
10149 Torino  
Italy

For the product

**HBV ELITe MGB® Kit for the quantitative detection of Hepatitis B virus DNA in human serum or plasma**

Documents, that form the basis of this certificate:


**Certification Notice 2110151CNCN, initially dated 26 February 2008**  
**CE Marking of Conformity 2110151CE05**  
**Addendum, initially dated 15 December 2021**

DEKRA hereby declares that the design of the product(s) falling within the product category mentioned above, fulfils the relevant provisions of 'Besluit in-vitro diagnostica', the Dutch transposition of the Council Directive 98/79/EC of October 27, 1998 concerning In vitro diagnostic medical devices, including all subsequent amendments, based on an examination in accordance with Annex IV (4) of this Directive. The manufacturer has implemented a quality assurance system for the above mentioned product category in accordance to the provisions of Annex IV (4) of Council Directive 98/79/EC of October 27, 1998 and is subject to periodical surveillance.

The necessary information and the reference to the relevant documentation, of the products concerned and the examinations and assessments performed, are stated in the Certification Notice which forms an integrative part of this certificate.

This certificate is valid until: 26 May 2025  
Issued for the first time: 15 December 2021  
Revised: 19 May 2022

DEKRA Certification B.V.

A blue ink signature of B.T.M. Holtus.

B.T.M. Holtus  
Managing Director

A blue ink signature of J.A. van Vugt.

J.A. van Vugt  
Certification Manager

© Integral publication of this certificate and adjoining reports is allowed

DEKRA Certification B.V. is Notified Body with ID no 0344

DEKRA Certification B.V. Meander 1051, 6825 MJ Arnhem P.O. Box 5185, 6802 ED Arnhem, The Netherlands  
T +31 88 96 83000 F +31 88 96 83100 www.dekra.nl Company registration 09085396



# ADDENDUM

Belonging to certificate: 2110151DE01

1/1

## EC DESIGN-EXAMINATION IN VITRO DIAGNOSTIC MEDICAL DEVICES

HBV ELITe MGB® Kit for the quantitative detection of Hepatitis B virus DNA in human serum or plasma

Issued to:


**Elitechgroup S.P.A.**  
Corso Svizzera 185  
10149 Torino  
Italy

This certificate covers the following product(s):

Product variants:  
HBV ELITe MGB Kit RTK602ING

Initial date: 15 December 2021

DEKRA Certification B.V.



B.T.M. Holtus  
Managing Director



J.A. van Vugt  
Certification Manager

© Integral publication of this certificate and adjoining reports is allowed

DEKRA Certification B.V. is Notified Body with ID no 0344

DEKRA Certification B.V. Meander 1051, 6825 MJ Arnhem P.O. Box 5185, 6802 ED Arnhem, The Netherlands  
T +31 88 96 83000 F +31 88 96 83100 www.dekra.nl Company registration 09085396



# EC DESIGN-EXAMINATION CERTIFICATE

Number: 2110151DE02

**Directive 98/79/EC on In Vitro Diagnostic Medical Devices, Annex IV (4)**  
(List A)

Manufacturer:

**ELITechGroup S.p.A.**

**Corso Svizzera 185  
10149 Torino  
Italy**

For the product

**HCV ELITe MGB® Kit for the quantitative detection of HCV virus RNA in human plasma and serum**

Documents, that form the basis of this certificate:

**Certification Notice 2110151CN, initially dated 26 February 2008**

**CE Marking of Conformity 2110151CE05**

**Addendum, initially dated 10 February 2022**


DEKRA hereby declares that the design of the product(s) falling within the product category mentioned above, fulfils the relevant provisions of 'Besluit in-vitro diagnostica', the Dutch transposition of the Council Directive 98/79/EC of October 27, 1998 concerning In vitro diagnostic medical devices, including all subsequent amendments, based on an examination in accordance with Annex IV (4) of this Directive. The manufacturer has implemented a quality assurance system for the above mentioned product category in accordance to the provisions of Annex IV (4) of Council Directive 98/79/EC of October 27, 1998 and is subject to periodical surveillance.

The necessary information and the reference to the relevant documentation, of the products concerned and the examinations and assessments performed, are stated in the Certification Notice which forms an integrative part of this certificate.

This certificate is valid until: 26 January 2025

Issued for the first time: 10 February 2022

DEKRA Certification B.V.



**B.T.M. Holtus**  
Managing Director



**J.A. van Vugt**  
Certification Manager

© Integral publication of this certificate and adjoining reports is allowed

DEKRA Certification B.V. is Notified Body with ID no 0344

DEKRA Certification B.V. Meander 1051, 6825 MJ Arnhem P.O. Box 5185, 6802 ED Arnhem, The Netherlands  
T +31 88 96 83000 F +31 88 96 83100 [www.dekra-product-safety.com](http://www.dekra-product-safety.com) Company registration 09085396



# ADDENDUM

Belonging to certificate: 2110151DE02

1/1

## EC DESIGN-EXAMINATION IN VITRO DIAGNOSTIC MEDICAL DEVICES

HCV ELITe MGB® Kit for the quantitative detection of HCV virus RNA in human plasma and serum

Issued to:


**ELITechGroup S.p.A.**  
Corso Svizzera 185  
10149 Torino  
Italy

This certificate covers the following product(s):

Product variants:  
HCV ELITe MGB® Kit RTK6011NG

Initial date: 10 February 2022

DEKRA Certification B.V.

A blue ink signature of B.T.M. Holtus.

B.T.M. Holtus  
Managing Director

A blue ink signature of J.A. van Vugt.

J.A. van Vugt  
Certification Manager

© Integral publication of this certificate and adjoining reports is allowed

DEKRA Certification B.V. is Notified Body with ID no 0344

DEKRA Certification B.V. Meander 1051, 6825 MJ Arnhem P.O. Box 5185, 6802 ED Arnhem, The Netherlands  
T +31 88 96 83000 F +31 88 96 83100 [www.dekra-product-safety.com](http://www.dekra-product-safety.com) Company registration 09085396



**ELITechGroup S.p.A**

Administrative and Operative Site

Sede Amministrativa ed Operativa

C.so Svizzera 185

10149 Torino (TO) - Italia

Tel : +39 011 97 61 91 Fax : +39 011 93 67 611

egspa.emd.info@elitechgroup.com

www.elitechgroup.com



Registered Office

Sede Legale

Corso Italia, 22

20122 Milano (MI) - Italia

MOD05,05-RTK601ING

Redatto da QM

Approvato da QARA

Rev. 02 del 25/05/2022, CC21-27, CC22-25

**DICHIARAZIONE CE DI CONFORMITÀ**  
**EC DECLARATION OF CONFORMITY**Nome del prodotto / *Product name***HCV ELITe MGB® Kit**Codice / *Ref***RTK601ING**Codice CND / *CND Code***W0105020307**Codice RDM / *RDM Code***2213375**Immissione sul mercato / *Placing on the market***23/02/2022**Classificazione / *Classification***Allegato II, elenco A / *Annex II, A list***Procedura di valutazione di conformità  
*Conformity assessment procedure***Allegato IV / *Annex IV***Marcatura CE / *CE Marking***CE 0344, DEKRA Certification B.V.**Documento di riferimento  
*Reference document***EC Certificate Number:**  
**2110151DE02**  
**2110151CE05****ELITechGroup S.p.A. dichiara che il prodotto è conforme alla Direttiva Dispositivi Medico Diagnostici in vitro 98/79/CE ed al D.Lgs. 332/2000****ELITechGroup S.p.A. declares product is in conformity with in vitro Diagnostic Medical Devices Directive 98/79/EC and with Legislative Decree 332/2000**

Pag 1/2



Fabbricante / *Manufacturer*

ELITechGroup S.p.A.  
C.so Svizzera 185 - 10149 Torino - ITALY  
Tel.: +39 011 976191 - FAX: +39 011 9367611

Sistema di Gestione per la Qualità  
*Quality Management System*

ISO 9001:2015; EN ISO 13485:2016

Organismo di certificazione  
*Certification body*

DEKRA Certification B.V.

Norme Armonizzate  
*Harmonized Standard*

EN ISO 18113-2:2011  
ISO 15223:2021  
EN 13612:2002  
EN ISO 23640:2015  
EN ISO 14971:2019

Data e Luogo /

*Date dd/mm/yyyy and Place  
signature*

25/05/2022, Torino

Firma Quality Assurance Regulatory Affairs / QARA





**ELITechGroup S.p.A**

Administrative and Operative Site

Sede Amministrativa ed Operativa

C.so Svizzera 185

10149 Torino (TO) - Italia

Tel : +39 011 97 61 91 Fax : +39 011 93 67 611

egspa.emd.info@elitechgroup.com

www.elitechgroup.com



Registered Office

Sede Legale

Corso Italia, 22

20122 Milano (MI) - Italia

MOD05,05-RTK602ING

Redatto da QM

Approvato da QARA

Rev. 01 del 25/05/2022, CC21-27, CC22-25

**DICHIARAZIONE CE DI CONFORMITÀ**  
**EC DECLARATION OF CONFORMITY**Nome del prodotto / *Product name*

HBV ELITe MGB® Kit

Codice / *Ref*

RTK602ING

Codice CND / *CND Code*

W0105020216

Codice RDM / *RDM Code*

2184915

Immissione sul mercato / *Placing on the market*

23/12/2021

Classificazione / *Classification*Allegato II, elenco A / *Annex II, A list*Procedura di valutazione di conformità  
*Conformity assessment procedure*Allegato IV / *Annex IV*Marcatura CE / *CE Marking*

CE 0344, DEKRA Certification B.V.

Documento di riferimento  
*Reference document*EC Certificate Number: 2110151DE01 and  
2110151CE05**ELITechGroup S.p.A. dichiara che il prodotto è conforme alla Direttiva Dispositivi Medico Diagnostici  
in vitro 98/79/CE ed al D.Lgs. 332/2000*****ELITechGroup S.p.A. declares product is in conformity with in vitro Diagnostic Medical Devices  
Directive 98/79/EC and with Legislative Decree 332/2000***



Fabbricante / *Manufacturer*

ELITechGroup S.p.A.  
C.so Svizzera 185 - 10149 Torino - ITALY  
Tel.: +39 011 976191 - FAX: +39 011 9367611

---

Sistema di Gestione per la Qualità  
*Quality Management System*

ISO 9001:2015; EN ISO 13485:2016

Organismo di certificazione  
*Certification body*

DEKRA Certification B.V.

---

Norme Armonizzate  
*Harmonized Standard*


EN ISO 18113-2:2011  
ISO 15223:2021  
EN 13612:2002  
EN ISO 23640:2015  
EN ISO 14971:2019

---

Data e Luogo /  
*Date dd/mm/yyyy and Place  
signature*

25/05/2022, Torino

Firma Quality Assurance Regulatory Affairs / QARA





**ELITechGroup S.p.A**

Administrative and Operative Site  
Sede Amministrativa ed Operativa  
C.so Svizzera, 185  
10149 Torino (TO) - Italia  
Tel : +39 011 97 61 91 Fax : +39 011 93 67 611  
egspa.emd.info@elitechgroup.com  
www.elitechgroup.com



Registered Office  
Sede Legale  
Corso Italia, 22  
20122 Milano (MI) - Italia

MOD05,05-IVDR- A\_Instruments  
Redatto da QM  
Approvato da QARA  
Rev.01 del 09/06/2022 RAC22-26

**DICHIARAZIONE DI CONFORMITÀ UE**  
**EU DECLARATION OF CONFORMITY**

Nome prodotti / <i>Products name</i>	Vedere lista dei prodotti allegata (Allegato Lista strumenti) <i>See attached list of products (Instruments list Annex)</i>
Codice / <i>Reference</i>	"
Codice Basic UDI-DI/ GMN <i>Basic UDI-DI/ GMN Code</i>	"
Codice UDI-DI / <i>UDI-DI Code</i>	"
Immissione in commercio / <i>Placing on Market</i>	"
Classe di Rischio / <i>Risk Class</i>	Vedere lista dei prodotti allegata <i>See attached list of products</i>
Procedura di valutazione di conformità <i>Conformity assessment Procedure</i>	"
Marcatura CE / <i>CE Marking</i>	CE

ELITechGroup S.p.A. dichiara sotto la sua esclusiva responsabilità che i sistemi ELITE InGenius® ed ELITE BeGenius® costituiti dallo strumento, dal software e dai dispositivi ad uso esclusivo, aventi come destinazione d'uso l'estrazione di DNA e RNA da campioni liquidi umani e l'esecuzione della reazione di PCR sono conformi al Regolamento 2017/746 sui Dispositivi Medico Diagnostici in vitro e alla Direttiva (UE) 2017/2102 (RoHS2) del Parlamento Europeo sulla restrizione dell'uso di determinate sostanze pericolose nelle apparecchiature elettriche ed elettroniche.

*ELITechGroup S.p.A. declares under its own exclusive responsibility the ELITE InGenius® and ELITE BeGenius® systems including instruments, software and exclusive use devices listed above, which its intended use is the extraction of DNA and RNA from human body liquid samples and the performing of a PCR reaction, is in conformity with Regulation 2017/746 on In vitro Diagnostic Medical Devices and the Directive (EU) 2017/2102 on the restriction of the use of certain hazardous substances in electrical and electronical equipment.*

Fabbricante / <i>Manufacturer</i>	ELITechGroup S.p.A. C.so Svizzera 185 - 10149 Torino - ITALY Tel.: +39 011 976191 - FAX: +39 011 9367611
Numero di Registrazione Unico <i>Single Registration Number</i>	IT-MF-000005919
Sistema di Gestione per la Qualità / <i>Quality Management System</i>	ISO 9001:2015; EN ISO 13485:2016
Organismo di certificazione /	



ELITechGroup S.p.A. (con unico socio)  
Società soggetta a direzione e coordinamento da parte di ELITechGroup S.a.S.  
Capitale Sociale € 1.000.000,00 i.v. Iscritta nel registro delle imprese di Milano  
C.F.P.IVA e n° di iscrizione 05239350969 – R.E.A. 1805944

Inviare tutta la corrispondenza alla sede Amministrativa di Torino





**ELITechGroup S.p.A**

Administrative and Operative Site  
Sede Amministrativa ed Operativa  
C.so Svizzera, 185

10149 Torino (TO) - Italia

Tel : +39 011 97 61 91 Fax : +39 011 93 67 611

egspa.emd.info@elitechgroup.com

www.elitechgroup.com



Registered Office

Sede Legale

Corso Italia, 22

20122 Milano (MI) - Italia

**Certification body**

**DEKRA Certification B.V.**

**Norme Armonizzate /**

**Harmonized Standards**

EN ISO 18113-2:2011

ISO 15223:2021

EN 13612:2002

EN ISO 23640:2015

EN ISO 14971:2019

IEC61010-1:2010/AMD1:2016

CEI EN 61326-2-6:2012

IEC 62304 :2015

IEC 62366-1:2015/AMD1:2020

**Luogo, Data / Place, Date dd/mm/yyyy**

**TORINO, 25/05/2022**

**Firma del Quality Assurance Regulatory Affairs / QARA Signature  
Person Responsible for Regulatory Compliance (PRRC) Signature**

**Nome Cognome / Name Surname : Sergio Fazari**



ASSOBIOMEDICA

ELITechGroup S.p.A. (con unico socio)

Società soggetta a direzione e coordinamento da parte di ELITechGroup S.a.S.

Capitale Sociale € 1.000.000,00 i.v. Iscritta nel registro delle imprese di Milano

C.F.P.IVA e n° di iscrizione 05239350969 – R.E.A. 1805944

Inviare tutta la corrispondenza alla sede Amministrativa di Torino





CODICE / CODE	NOME / NAME	Data di immissione in commercio in accordo a IVDD / Placing date on the market according to IVDD	Data di immissione in commercio in accordo a IVDR / Placing date on the market according to IVDR	Classe di Rischio / Risk Class	UDI-DI di Base / Basic UDI-DI	Codice UDI-DI / UDI-DI Code	2017/746 Allegato / Annex	Codice EMDN / EMDN Code	Descrizione EMDN / EMDN Description	Codice RDM / RDM Code
INT030	ELiTe InGenius®	05/08/2015	26/05/2022	A	366154090S2R005R	03661540900013	IX	W02050116	Nucleic Acid Testing Integrated extraction/Amplification/Detection Systems	2258247
INT040	ELiTe BeGenius®	12/07/2021	26/05/2022	A	366154090S2R005R	03661540900028	IX	W02050116	Nucleic Acid Testing Integrated extraction/Amplification/Detection Systems	2258248





# ELITE *InGenius* Combo-Panels

Assemble your syndromic test

## Pathogens Monitoring in Immunocompromised

CMV	PARVOVIRUS B19	HHV8
EBV	ADENOVIRUS	HEV
BKV	ENTEROVIRUS	T. GONDII
VZV	JCV	ASPERGILLUS
HSV1	HHV6	P. JIROVECII
HSV2	HHV7	WNV <sup>°</sup>

### LEGEND:

Blue = ELITE MGB® Kit  
 Green = Third Party Kit compatible with ELITE InGenius®  
<sup>°</sup> = RUO  
 \* = under development  
 ■ = qualitative e quantitative

## Sexually Transmitted Infections

**STI PLUS**  
 C. trachomatis  
 N. gonorrhoeae  
 M. genitalium  
 T. vaginalis

**MACROLIDE-R/MG**  
*M. genitalium*  
 Macrolide Resistance

**C. TRACHOMATIS**

**HPV**  
 16  
 18  
 Other High Risks

**HSV 1/2**

**STI PLUS CMT**  
 C. trachomatis  
 M. genitalium  
 T. vaginalis

## Respiratory Infections

**SARS-CoV-2 PLUS**  
 SARS-CoV-2  
 Flu A  
 Flu B  
 RSV

**MDR/MTB**  
 MTB Complex  
 Rifampicin Resistance  
 Isoniazid Resistance

**Respiratory Viral PLUS**  
 Flu A/ Flu B  
 RSV/ hMPV

**SARS-CoV-2 ■**

**BORDETELLA**  
*Pertussis*  
*Parapertussis*  
*Holmesii*

**BACTERIAL PANEL**  
*M. pneumoniae*  
*C. pneumoniae*  
*Legionella pn.*

**SARS-CoV-2 Variants <sup>°</sup>**

**ASPERGILLUS**

**P. JIROVECII**



## Meningitis & Encephalitis

### VIRAL PANEL

HSV1  
HSV2  
VZV

### VIRAL PANEL 2

Enterovirus  
Parechovirus  
Adenovirus

### BACTERIAL PANEL

*N. meningitidis*  
*S. pneumoniae*  
*H. influenzae*  
*H. Influenzae type B*

## Viral Load

HBV \*

HCV \*

HEV

## HIV and related assays

HIV-1 \*

HHV8

P. JIROVECII

ASPERGILLUS

HLA-B57

CYP2C9-2

CYP2C9-3

## Gastrointestinal Infections

### NOROVIRUS PANEL

Genotypes I & II

### VIRAL PANEL

Rotavirus  
Adenovirus  
Astrovirus

## Oncohematology

BCR-ABL P210	RNA REFERENCE
BCR-ABL P190	

## Healthcare Associated Infections

MRSA/SA <i>S. aureus</i> <i>mecA/mecC</i>	CRE KPC IMP/VIM/NDM OXA 48	ESBL CTX-M-1/15 CTX-M-9/14
C. difficile Toxin A Toxin B	Colistin/R <i>mcr1</i> <i>mcr2</i>	P. JIROVECII

## Genetics

COAGULATION Factor V Factor II MTHFR	APOE	BETA-FIBRINOGEN	CYP2C9-2	CYP2C9-3
	MTHFR A1298C	FACTOR V H1299R	FACTOR XIII – V34L	HFE C282Y
	HFE S65C	HPA-1 A/B	HLA-B57	PAI-1 4G/5G
				VKORC1

## Zoonosis - Other infections

WNV °	ZIKA	DENGUE	CHIKUNGUNYA	LEISHMANIA
	MALARIA <i>P. Falciparum</i> , <i>P. Ovale</i> , <i>P. Malariae</i> , <i>P. Viva</i>	MALARIA SCREENING <i>P. Falciparum</i> , <i>P. Ovale</i> , <i>P. Malariae</i> , <i>P. Viva</i> , <i>P. Knowlesi</i>		MEASLES VIRUS



### WORLDWIDE OFFICES

Please contact your sales representative for terms, conditions and product availability in your country.



ELITechGroup is certified by DEKRA and applies a quality management system in compliance with ISO 9001:2015 and EN ISO 13485:2016

Limited license : Please visit <http://www.elitechgroup.com/corporate/elitemgb-legalnotice> for complete licensing and warranty information. ELITE MGB® is a registered trademark of ELITechGroup. Products not available in the US.

### Headquarters

Australia  
Belgium, Luxemburg  
Brazil  
France  
Italy

+33 1 41 45 07 10  
+61 1800 815 098  
+32 9 282 05 31  
+55 27 3025 1415  
+33 4 83 36 10 82  
+39 011 97 61 91

New Zealand  
Serbia  
The Netherlands  
UK  
United States

+64 800 555 611  
+381 11 2467119  
+31 313 430 500  
+44 1442 869 320  
+1 800 453 2725



**ELITechGroup**

EMPOWERING IVD

[www.elitechgroup.com](http://www.elitechgroup.com)  
[info@elitechgroup.com](mailto:info@elitechgroup.com)





42 CE-IVD Real Time PCR assays to cover different clinical applications



## Pathogens Monitoring in Immunocompromised

<b>CMV</b> 1 2 4 5 9 11 14 19	<b>PARVOVIRUS B19</b> 1 11	<b>HHV8</b> 1 2
<b>EBV</b> 1 2	<b>ADENOVIRUS</b> 1	<b>HEV</b> 2 10
<b>BKV</b> 2 5	<b>ENTEROVIRUS</b> 2 4	<b>T. GONDII</b> 1 4 11
<b>VZV</b> 1 2 4	<b>JCV</b> 2 4 5	<b>ASPERGILLUS</b> 2 9 19
<b>HSV1</b> 1 2 4	<b>HHV6</b> 1 2	<b>P. JIROVECII</b> 9 13
<b>HSV2</b> 1 2 4	<b>HHV7</b> 1 2	<b>WNV**</b> 1 4 5



## Meningitis & Encephalitis

<b>VIRAL PANEL</b> 4 HSV1 HSV2 VZV	<b>VIRAL PANEL 2</b> 4 Enterovirus Parechovirus Adenovirus	<b>BACTERIAL PANEL</b> 1 4 <i>N. meningitidis</i> <i>S. pneumoniae</i> <i>H. influenzae</i> <i>H. influenzae</i> type B
---	---	---



## Healthcare Associated Infections

<b>CRE</b> 8 12 9* 25* KPC IMP-VIM-NDM OXA	<b>COLISTIN-R</b> 8 <i>mcr1</i> <i>mcr2</i>	<b>C. DIFFICILE</b> 10 Toxin A Toxin B
<b>ESBL</b> 8 12 9* 25* CTX-M-1,15 CTX-M-9,14	<b>MRSA/SA</b> 6 12 9* 25* <i>S. aureus</i> <i>mecA / mecC</i>	



## Sexually Transmitted Infections

<b>STI PLUS</b> 5 15 16 <i>C. trachomatis</i> <i>N. gonorrhoeae</i> <i>M. genitalium</i> <i>T. vaginalis</i>	<b>MACROLIDE-R/MG</b> 5 15* 16* <i>M. genitalium</i> Macrolide resistance	<b>HPV</b> 15 16 16 18 Other High Risks
<b>HSV1/2</b> 22	<b>C. TRACHOMATIS</b> 5 15 16	



## Gastrointestinal Infections

<b>VIRAL PANEL</b> 10 Rotavirus Adenovirus Astrovirus	<b>NOROVIRUS PANEL</b> 10 Genotypes I & II
--	---



## Respiratory Infections

<b>MTB EXTRA</b> 5 9 13 17 18 MTB complex	<b>BACTERIAL PANEL</b> 9 <i>M. pneumoniae</i> <i>C. pneumoniae</i> <i>Legionella pn.</i>	<b>Respiratory Viral PLUS</b> 9 21 Flu A Flu B RSV hMPV*
<b>MDR/MTB</b> 5 9 13 17 18 MTB complex Rifampicin resistance Isoniazid resistance	<b>SARS-COV-2 PLUS</b> 6 7 21 SARS-CoV-2 Flu A Flu B RSV	<b>SARS-COV-2</b> 6 7 14 21 <b>SARS-CoV-2 Variants °</b> <b>P. JIROVECII</b> 9 13 <b>ASPERGILLUS</b> 2 9 19
<b>BORDETELLA</b> 23 <i>B. pertussis</i> <i>B. parapertussis</i> <i>B. holmesii</i>		

## 25 Matrices

Universal Extraction for several samples

- 1 Whole Blood
- 2 Plasma
- 3 Serum
- 4 CSF
- 5 Urine
- 6 Nasal Swabs
- 7 Throat Swabs
- 8 Rectal Swabs
- 9 BAL
- 10 Stool
- 11 Amniotic Fluid
- 12 Blood Culture
- 13 Sputum
- 14 Saliva/Buccal Swabs
- 15 Cervical Swabs
- 16 Vaginal Swabs
- 17 Cavitary Fluid
- 18 Biopsies/Tissue
- 19 Bronchial Aspirate (BA)
- 20 Gastric Aspirates
- 21 Nasopharyngeal Swabs
- 22 Cutaneous/Mucoc. Swabs
- 23 Nasopharyngeal Aspirate
- 24 White Blood Cells
- 25 Culture Isolates

\* Under Development  
\*\* Available in Open Mode  
° RUO





# ELiTe BeGenius<sup>®</sup>

FULLY INTEGRATED SAMPLE-TO-RESULT SOLUTION FOR MOLECULAR DIAGNOSTICS

CUSTOMER PRESENTATION – ENGLISH VERSION \_OCT 2021\_V0.1





# Foreword

The laboratory is alive

Laboratory is an evolving environment constantly looking for new solutions



## Be part of the change

# Introduction





# ELITe BeGenius®

## Introduction



# ELITE BeGenius®

## Introduction





# Features & benefits




# Be Smart

Tailored to your needs



- < Stand alone system with compact footprint
- < Cooled storage of samples, eluates, and reagents to improve their stability on-board
- < Total traceability of samples, eluates and reagents with bidirectional LIS connection
- < Compatibility to several different primary tubes
- < Availability of a wide range of CE-IVD assays and open channel capability

**CLEVER ANSWER TO ANY  
WORKFLOW**





# Be Easy

Molecular biology becomes universally accessible



- < Walk away solution: reduced hands on time, full automation and intuitive software
- < Different matrices and different assays can be run simultaneously
- < Capable to manage 24 independent PCR protocols
- < BeGenius uses the same reagents and consumables as InGenius
- < Build up your molecular corner as you wish with BeGenius

**OPERATE YOUR MOLECULAR LAB  
ACCORDING TO YOUR NEEDS**



# Be Power

Boost your lab efficiency



- < Run up to 72 results in a 8h shift. Up to 18.000 tests/year
- < Fast mode with 2 ml primary tubes, up to 12 reports in less than 2 hours
- < Run many assays from the same sample patient
- < Up to 24 different samples in several kinds of matrices can be tested in parallel within the same run

**FIRST RESULTS IN LESS THAN 2  
HOURS AND UP TO 18.000  
TESTS/YEAR**



The “Genius Way”






# Welcome to the “Genius Way” era

BeGenius and InGenius melts into the “Genius” concept



12 Genius Ways Modules



**“Genius Way” grows with your needs**

# Growing with the customers


The "Genius Way" grows with your laboratory

The "Genius Way" is the solution  
for your laboratory today and in  
the future



**We help you to identify your needs and offer  
tailored solutions for your laboratory**

**Improve routine  
workflow & speed**



# Genius Way

whatever kind of laboratory you are  
*ELITechGroup has the solution for you*

**Consolidation &  
in-sourcing**



# Message to Labs



# Message to Labs

Be Part of the Change



## Universal access to molecular biology

Easy solution, ideal for molecular experts and beginners

Compact and self-standing, fits into any lab

## Growing with the customer

Capable to manage 24 independent PCR protocols

Up to 24 samples from different matrices can be tested in parallel within the same run

Broad range of CE-IVD assays and defined IVDR roadmap

## Tailored to every routine

Easy to set up, less than two minutes hands-on-time per sample

Walk away solution, fully automated



# Solutions rather than products



[elitechgroup.com](http://elitechgroup.com)

[egspa.marketing@elitechgroup.com](mailto:egspa.marketing@elitechgroup.com)




# HIV1 ELITe MGB® Kit

**Quantitative assay for the detection and quantification  
of the RNA of HIV1**



# HIV1 RNA

## Key Facts



Human immunodeficiency virus (HIV) is an infection that attacks the body's immune system, specifically CD4 cells

WHO recommends that every person who may be at risk of HIV should access testing

The treatment goal is to reduce the viral load in the blood to undetectable levels (**less than 50 copies/ml**)


<https://apps.who.int/iris/bitstream/handle/10665/259638/EndAIDS-eng.pdf;sequence=1>

**WHO set a GLOBAL target of ending the HIV/AIDS epidemic by 2030**

# Burden of HIV Infection

WHO 2021

**Number of people acquiring HIV and number of people dying from HIV-related causes, 2020**



Data source: World Health Organization (2021). Global Progress Report 2021: HIV, viral hepatitis and sexually transmitted infections. Overview of the Global Health Sector Strategies, past and future.



# Monitoring for HIV-1 treatment response

## WHO HIV guidelines

The guidelines state that HIV1 RNA be monitored at least two times for year during treatment

Viral load is recommended as the preferred monitoring approach to diagnose and confirm treatment failure

International guidelines suggest a value of **50 copies/ml of HIV RNA** as the threshold below which 'therapeutic success' is considered to have been achieved.

**REAL-TIME PCR IS THE PREFERRED METHOD FOR MONITORING HIV1 PATIENTS DURING TREATMENT**

<https://apps.who.int/iris/rest/bitstreams/1336192/retrieve>





# Assay Presentation

# HIV1 ELITe MGB<sup>®</sup> Kit

**RTK600ING – Intended Use**



- Quantitative assay for the detection and quantification of the RNA of HIV1
- Detection and quantification of HIV1 group M (subtypes from A to L), group O, group N and main **CRF's (CRF03-AB)**.
- Intended for the management of HIV1-infected individuals undergoing antiviral therapy (monitoring)

**INDICATED FOR MONITORING  
PATIENTS DURING ANTIVIRAL  
THERAPY**



# HIV1 ELITe MGB® Kit

## RTK600ING – Main characteristics



- **Specific targets:** Integrase region (pol domain)
- **Internal Control:** exogenous based on MS2 genomic RNA
- **Matrices:** Plasma in EDTA and ACD
- **Extraction:** SP1000 (600µl-50µl)
- **CE-IVD validated:** ELITe InGenius®
- **Compatibility Thermal cyclers:** 7500 Fast Dx Real-Time PCR

**INDICATED FOR MONITORING  
PATIENTS DURING ANTIVIRAL  
THERAPY**



# HIV1 ELITe MGB® Kit

## Performances

### Limit of Detection for Plasma samples

<b>IU/mL</b>	<b>60</b>
<b>Copies/mL</b>	<b>26</b>
<b>Diagnostic Specificity*</b>	<b>99.5%</b>

\* Vs Method Comparison. Please refer to IFU SCH mRTK600ING\_02\_N

### Linear measuring range for Plasma samples

<b>Lower Limit</b>	<b>Upper Limit</b>
60 IU / mL	3,19x10 <sup>8</sup> IU / mL
26 copies / mL	1,38x10 <sup>8</sup> copies / mL

WHO International Standard "4th WHO International Standard for HIV-1" (NIBSC code: 16/194) in Plasma collected in ACD.  
6 dilution levels and 24 replicates for each level


**OPTIMAL SENSITIVITY FOR HIV1  
MONITORING**



# HIV1 ELITe MGB® Kit

## Method correlation

Plot of Log cp/mL HIV1 ELITe MGB Kit vs Log cp/mL Cobas HIV-1 with Fitted Lines  
Error Variance Ratio (Log cp/mL HIV1 ELITe MGB Kit/Log cp/mL Cobas HIV-1) = 1



Orthogonal:  $\text{Log cp/mL HIV1 ELITe MGB Kit} = -0.125 + 1.040 \text{ Log cp/mL Cobas HIV-1}$   
Least Squares:  $\text{Log cp/mL HIV1 ELITe MGB Kit} = -0.059 + 1.020 \text{ Log cp/mL Cobas HIV-1}$

The Orthogonal and the Linear Regressions were performing by Minitab 19 statistical software (Figure 1) on the 141 samples.




**Orthogonal Regression:** intercept equal to -0.125 and slope equal to 1.040

**Linear Regression:** R equal to **0.964**

**EXCELLENT CORRELATION WITH  
REFERENCE METHOD**

# HIV1 ELITe MGB® Kit

**RTK600ING – 96 tests assay**



**EVERYTHING YOU NEED IN ONE BOX**

# HIV1 ELITe MGB<sup>®</sup> Kit

Main characteristics: MGB mix & Internal Control

**HIV1 ELITe MGB Mix      600µl**



**x 4**

**HIV1 Internal Control      160µl**



**x 8**

## HIV1 ELITe MGB Mix (White Cap)

- 4 tube ready to use PCR MIX
- 24 test/tube
- 5 freeze-thaw cycles


## HIV1 Internal Control ( Grey Cap)

- 8 tubes ready to use
- 12 session / tube
- 12 freeze-thaw cycles

**THE SINGLE BOX KIT CONTAINS ALL  
REQUIRED READY-TO-USE REAGENTS,  
STANDARDS AND CONTROLS**

A  
S  
S  
A  
Y

I  
C






# HIV1 ELITe MGB<sup>®</sup> Kit

Main characteristics: Positive Control & Standard

## HIV1 ELITe MGB Mix 160µl



## HIV1 Positive Control 160µl



x 2

## HIV1 ELITe Standard

- HIV ELITe Standard  $10^5$  – 1 tube 160 µL (Red Cup)
- HIV ELITe Standard  $10^4$  – 1 tube 160 µL (Blue Cup)
- HIV ELITe Standard  $10^3$  – 1 tube 160 µL (Green Cup)
- HIV ELITe Standard  $10^2$  – 1 tube 160 µL (Yellow Cup)
- 4 tubes ready to use
- 2 session / tube
- 2 freeze – thaw cycles
- **Calibration to be performed every 60 days**


## HIV1 - ELITe Positive Control (Black cap)

- 2 tubes ready to use
- 4 session / tube in association with ELITe InGenius<sup>®</sup>.
- 4 freeze – thaw cycles
- **Positive control to be performed every 15 days**

**THE SINGLE BOX KIT CONTAINS ALL  
REQUIRED READY-TO-USE REAGENTS,  
STANDARDS AND CONTROLS**

S  
T  
A  
N  
D  
A  
R  
D

P  
C



# HIV1 ELITe MGB<sup>®</sup> Kit

## Features

**OPTIMAL SENSITIVITY: LIMIT OF DETECTION (LOD) EQUAL TO  
26 COPIES/ML**

**OPTIMAL QUANTIFICATION OVER THE RANGE  
26- 1,38x10<sup>8</sup>COPIES/ML**

**PERFECT CORRELATION BETWEEN THE GENIUS SYSTEM  
AND THE REFERENCE METHOD**

**DIFFERENT SAMPLE TYPES TESTING (E.G. CSF)**

**SINGLE SAMPLE TESTING WITHOUT ANY WASTE**

**A NEW SOLUTION FOR THE  
QUANTIFICATION OF HIV1 RNA**

# HCV ELITe MGB® Kit

**Quantitative assay for the detection and  
quantification of HCV RNA**



# HCV RNA- Hepatitis C virus

## Key Facts

The Hepatitis C virus can cause both acute and chronic hepatitis, lifelong illness including liver cirrhosis and cancer.

The hepatitis C virus is a bloodborne virus and most infection occur through exposure to:

- blood from unsafe injection practices
- unscreened blood transfusions
- injection drug use


Antiviral therapy can cure more than 95% of persons with hepatitis C infection, but access to diagnosis and treatment is low

**WHO GLOBAL GOAL IS TO STOP HCV BY 2030**

<https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>

# Burden of HCV Infection

## WHO 2021



Data source: World Health Organization (2021). Global Progress Report 2021: HIV, viral hepatitis and sexually transmitted infections. Overview of the Global Health Sector Strategies, past and future.



# Monitoring for HCV treatment response

## WHO HCV guidelines

**WHO recommend quantitative HCV RNA testing prior to initiating antiviral therapy and at the end of treatment after 12 or 24 weeks.**

Guidelines from the AASLD\* suggest testing for quantitative HCV RNA at periodic intervals during treatment (e.g. 4 weeks).

WHO recommends therapy with direct-acting antivirals (DAAs) for persons over the age of 12 years.

The goal of HCV therapy is defined as undetectable HCV RNA with a **detection limit < 25 IU/ml after therapy.**

**REAL-TIME PCR IS THE PREFERRED METHOD FOR MONITORING HCV PATIENTS DURING TREATMENT**

\* American Association for the Study of Liver Disease





# Assay Presentation

# HCV ELITe MGB® Kit

**RTK601ING – Intended Use**



- Quantitative assay for the detection and quantification of the RNA of Hepatitis C virus (HCV)
- Detection and quantification of HCV genotypes **1, 2, 3, 4, 5 and 6**
- Intended for the management of HCV- infected individuals undergoing antiviral therapy (monitoring)

**INDICATED FOR MONITORING  
PATIENTS DURING ANTIVIRAL  
THERAPY**



# HCV ELITe MGB<sup>®</sup> Kit

## RTK601ING – Main characteristics



- **Specific targets:** Sequence 5' UTR
- **Internal Control:** RNA of MS2 phage
- **Matrices:** Plasma in EDTA and ACD, Serum
- **Extraction:** SP1000 (600µl-50µl)
- **CE-IVD validated:** ELITe InGenius<sup>®</sup>
- **Compatibility Thermal cyclers:** 7500 Fast Dx Real-Time PCR

**INDICATED FOR MONITORING  
PATIENTS DURING ANTIVIRAL  
THERAPY**

# HCV ELITe MGB® Kit

## Performances

Limit of Detection for Plasma and Serum samples	
IU/ml	26
Copies/ml	11
Diagnostic Specificity*	100%

\* Vs Method Comparison. Please refer to IFU SCH mRTK601ING\_02\_N

Linear measuring range for Plasma and serum samples	
Lower Limit	Upper Limit
26 IU / mL	$2,5 \times 10^7$ IU / mL
11 copies / mL	$10 \times 10^6$ copies / mL

The linearity of quantification was verified by analysis of negative Plasma collected in EDTA spiked by HCV reference material (SeraCare) for main HCV genotypes (1, 2, 3, 4, 5, 6). Each HCV genotype was tested in a panel of 6 dilution levels.


**OPTIMAL QUANTIFICATION OVER THE  
LINARITY RANGE**



# HCV ELITe MGB<sup>®</sup> Kit

## Method correlation

Plot of Log IU/mL HCV ELITe MGB Kit vs Log IU/mL Cobas HCV with Fitted Lines  
Error Variance Ratio (Log IU/mL HCV ELITe MGB Kit/Log IU/mL Cobas HCV) = 0.8






- **Orthogonal Regression:** intercept equal to 0.651 and slope equal to **0.894**
- **Linear Regression:** R equal to **0.916**

The Orthogonal and the Linear Regressions were performing by Minitab 19 statistical software (Figure 1) on the 137 samples.

**EXCELLENT CORRELATION WITH  
REFERENCE METHOD**

# HCV ELITe MGB<sup>®</sup> Kit

RTK601ING – 96 tests assay



**ALL YOU NEED IS IN ONE BOX**

# HCV ELITe MGB<sup>®</sup> Kit

Main characteristics: MGB mix & Internal Control

**HCV ELITe MGB Mix 600µl**



**x 4**

**HCV Internal Control 160µl**



**x 8**

## HCV ELITe MGB Mix (White Cap)

- 4 tube ready to use PCR MIX
- 24 test/tube
- 5 freeze-thaw cycles


## HCV Internal Control ( Grey Cap)

- 8 tubes ready to use
- 12 session / tube
- 12 freeze-thaw cycles

**THE SINGLE BOX KIT CONTAINS ALL  
REQUIRED READY-TO-USE REAGENTS,  
STANDARDS AND CONTROLS**

A  
S  
S  
A  
Y


I  
C



# HCV ELITe MGB<sup>®</sup> Kit

Main characteristics: Positive Control & Standard

## HCV ELITe Standard 160µl



## HCV ELITe Positive Control 160µl



x 2

### HCV ELITe Standard

- HCV ELITe Standard  $10^5$  – 1 tube 160 µL (Red Cup)
- HCV ELITe Standard  $10^4$  – 1 tube 160 µL (Blue Cup)
- HCV ELITe Standard  $10^3$  – 1 tube 160 µL (Green Cup)
- HCV ELITe Standard  $10^2$  – 1 tube 160 µL (Yellow Cup)
- 4 tubes ready to use
- 2 session / tube
- 2 freeze – thaw cycles
- **Calibration to be performed every 60 days**


### HCV - ELITe Positive Control (Black cap)

- 2 tubes ready to use
- 4 session / tube in association with ELITe InGenius<sup>®</sup>.
- 4 Freeze – thaw cycles
- **Control to be performed every 15 days**

**THE SINGLE BOX KIT CONTAINS ALL  
REQUIRED READY-TO-USE REAGENTS,  
STANDARDS AND CONTROLS**

S  
T  
A  
N  
D  
A  
R  
D

P  
C



# HCV ELITe MGB<sup>®</sup> Kit

## Features

**LIMIT OF DETECTION (LOD) EQUAL TO 26 COPIES/ML**

**OPTIMAL QUANTIFICATION OVER THE RANGE  
26 IU / mL -  $2,5 \times 10^7$  IU / mL**

**PERFECT CORRELATION BETWEEN THE GENIUS SYSTEM  
AND THE REFERENCE METHOD**

**POSSIBILITY OF ELUATE RECOVERY FOR FURTHER DIAGNOSTIC  
INVESTIGATIONS (I.E HCV GENOTYPING)**

**SINGLE SAMPLE TESTING WITHOUT ANY WASTE**

**A NEW SOLUTION FOR THE  
QUANTIFICATION OF HCV RNA**




# HBV ELITe MGB® Kit

**Quantitative assay for the detection and quantification  
of Hepatitis B virus DNA**



# HBV – Hepatitis B virus

## Key Facts



Hepatitis B is a contagious disease caused by HBV and is a leading cause of liver cancer

The virus can be transmitted in various ways:

- from mother to newborn during delivery
- blood contact/transfusions
- sexual relations with an infected partner
- unsafe injections and cuts from sharp instruments


HBV transmission from mother to newborn is the leading cause of chronic infection.

**WHO GLOBAL GOAL IS TO STOP HEPATITIS BY 2030**

<https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>

# Burden of HBV infection

WHO 2021



Data source: World Health Organization (2021). Global Progress Report 2021: HIV, viral hepatitis and sexually transmitted infections. Overview of the Global Health Sector Strategies, past and future.

# Monitoring for HBV treatment response

WHO HBV 2017 guidelines

**The WHO guidelines recommends monitoring HBV DNA at least annually during treatment**

Quarterly monitoring is strongly recommended in the following situations:

- Patients with advanced disease
- Evaluation of therapy effectiveness during the first year of treatment
- Treatment response is not effective
- In people affected by HIV co-infection
- Follow-up after completing the treatment for 1 year

**REAL-TIME PCR IS THE PREFERRED METHOD FOR MONITORING HBV PATIENTS DURING TREATMENT**



# Assay Presentation



# HBV ELITe MGB<sup>®</sup> Kit

RTK602ING – Intended Use



- Quantitative assay for the detection and quantification of hepatitis B virus (HBV) DNA.
- Detection and quantification of HBV Genotypes **A to I and RF**
- Intended for the management of HBV-infected individuals undergoing antiviral therapy (monitoring)

**THE PRODUCT IS INDICATED FOR  
MONITORING PATIENTS DURING  
ANTIVIRAL THERAPY**



# HBV ELITe MGB<sup>®</sup> Kit

## RTK602ING – Main characteristics



- **Specific targets:** Polymerase gene (TP domain)
- **Internal Control:** Plasmid DNA contains the sequence IC2
- **Matrices:** Plasma in EDTA or ACD and Serum
- **Extraction:** SP200 (200µl-50µl)
- **CE-IVD validated:** ELITe InGenius<sup>®</sup>
- **Compatibility Thermal cyclers:** 7500 Fast Dx Real-Time PCR

**THE PRODUCT IS INDICATED FOR  
MONITORING PATIENTS DURING  
ANTIVIRAL THERAPY**

# HBV ELITe MGB® Kit

## Performances

<b>Limit of Detection</b> for Plasma and serum samples	
<b>IU/ml</b>	<b>9</b>
<b>Copies/ml</b>	<b>38</b>
<b>Diagnostic Specificity</b>	<b>97,6%</b>
<b>Linear measuring range</b> for Plasma EDTA samples	
<b>Lower Limit</b>	<b>Upper Limit</b>
9 IU / mL	3,17x 10 <sup>8</sup> IU / mL
38 copies / mL	1,3 x 10 <sup>9</sup> copies / mL


The LoD was defined by testing a panel of HBV negative Plasma collected in ACD spiked by HBV certified reference material (4th WHO International Standard, NIBSC) at known title. Six levels of dilutions were prepared starting from 18 IU/mL to 1 IU/mL.

**OPTIMAL SENSITIVITY FOR HBV  
MONITORING**



# HBV ELITe MGB® Kit

## Method correlation








Over 131 plasma samples with titer within the linearity measurement range, regression analysis showed excellent correlation between HBV ELITe MGB Kit®-ELITe InGenius® and cobas® HBV kit, with an intercept equal to 0.085 (95% CI: -0.009 – 0.179), a slope equal to 0.987 (95% IC: 0.959 – 1.015) and R2 equal to 0.974.

- **Orthogonal Regression:**  
Intercept equal to 0.085 and slope equal to **0.987**
- **Linear Regression:**  
R equal to **0.974**

**EXCELLENT CORRELATION WITH  
REFERENCE METHOD**

# HBV ELITe MGB<sup>®</sup> Kit

RTK602ING – 96 tests assay



**ALL YOU NEED IS IN ONE BOX**




# HBV ELITe MGB<sup>®</sup> Kit

Main characteristics: MGB mix & Internal Control

HBV ELITe MGB Mix 280µl



HBV Internal Control 160µl



## HBV ELITe MGB Mix (White Cap)

- 8 tubes ready to use PCR MIX
- 12 tests/tube
- 7 freeze-thaw cycles


## HBV Internal Control ( Grey Cap)

- 8 tubes ready to use
- 12 tests / tube
- 12 freeze-thaw cycles

**THE SINGLE BOX KIT CONTAINS ALL  
REQUIRED READY-TO-USE REAGENTS,  
STANDARDS AND CONTROLS**

A  
S  
S  
A  
Y

I  
C






# HBV ELITe MGB® Kit

Main characteristics: Positive Control & Standard

## HBV ELITe Standard 160µl



## HBV ELITe Positive Control 160µl



x 2

## HBV ELITe Standard

HBV ELITe Standard 105 – 1 tube 160 µL (Red Cup)  
HBV ELITe Standard 104 – 1 tube 160 µL (Blue Cup)  
HBV ELITe Standard 103 – 1 tube 160 µL (Green Cup)  
HBV ELITe Standard 102 – 1 tube 160 µL (Yellow Cup)

- 4 tubes ready to use
- 2 session /tube
- 2 freeze – thaw cycles
- **Calibration to be performed every 60 days**


## HBV - ELITe Positive Control (Black cap)

- 2 tubes ready to use
- 4 session / tube
- 4 Freeze – thaw cycles
- **Positive control to be performed every 15 days**

**THE SINGLE BOX KIT CONTAINS ALL  
REQUIRED READY-TO-USE REAGENTS,  
STANDARDS AND CONTROLS**

S  
T  
A  
N  
D  
A  
R  
D

P  
C



# HBV ELITe MGB<sup>®</sup> Kit

## Features

**LIMIT OF DETECTION (LOD) EQUAL TO 9 IU/ML**

**OPTIMAL QUANTIFICATION OVER THE RANGE  
9 IU/ML -  $3,17 \times 10^8$  IU/mL**

**PERFECT CORRELATION BETWEEN THE GENIUS SYSTEM  
AND THE REFERENCE METHOD**

**POSSIBILITY OF ELUATE RECOVERY FOR FURTHER DIAGNOSTIC  
INVESTIGATIONS**

**SINGLE SAMPLE TESTING WITHOUT ANY WASTE**

**A NEW SOLUTION FOR THE  
QUANTIFICATION OF HBV DNA**



# BBV ELITe MGB® Solution Features

# BBV ELITe MGB® Kit

**Solution suitable to all laboratories**



**AVAILABLE FROM Q4 2022**

**EASE OF USE**

**MINIMUM «HANDS ON TIME»**

**RESULTS IN LESS THAN 3 HOURS**

**SINGLE SAMPLE TESTING WITHOUT ANY WASTE**

**RAPID RESULTS SUPPORT BETTER PATIENT  
MANAGEMENT**

**WE OFFER THE BEST GENIUS WAY  
SOLUTION FOR YOUR LAB**

# Welcome to the “Genius Way” era

BeGenius and InGenius combine forces into one unified into the “Genius” concept



## InGenius

Throughput: **36/samples/8 hours**

Pos ID: **NO**

Eluate Storage: **YES**

BBV Primary Tube Loading: **NO**

Different extraction protocols: **NO**



## BeGenius

Throughput: **72/samples/8 hours**

Pos ID: **YES**

Eluate Storage: **YES**


BBV Primary Tube Loading: **YES**

Different extraction protocols: **YES**

**Genius Way unlimited the scalability that ensures a future for any laboratory**


# Universality

Of the "Genius" series



+ Routine

+ Urgent



Results +

< QUALITATIVE ASSAY

< QUANTITATIVE ASSAY

< MULTIPLEX OR  
SINGLEPLEX



# Genius® Menu

Complete panel for detecting and monitoring Hepatitis and HIV 1 related pathogens

## Blood borne Panel

HBV

HCV

HEV

HIV1

HAV

## HIV Related Test

HIV1

HHV8

P. JIROVECII

ASPERGILLUS

HLA-B5701

**Blue** = Validated Kit  
**Green** = Compatible Kit


MEET CLINICAL NEEDS WITH OUR  
COMPREHENSIVE MENU



# EG Solution Positioning

# BBV ELITe MGB® Kit

## Target customer



**IDEAL TARGET : 500-5000 tests/year**



# POSITIONING

## Target Customers

### Medium realities (5000-10000 test/year)

Labs with complex dynamics seeking simplification, synergy and optimization



### Small – Medium realities (500-5000 test/year)

Local facilities looking for fast response, in-sourcing and growth



# Competition

# HIV1 ELITe MGB® Kit

## Competition chart



<b>KIT</b>	HIV1 ELITe MGB® KIT	Cobas® HIV Test	Cobas® HIV Test	Real Time HIV-1	ALINITY m HIV-1 ASSAY
<b>IVD</b>	CE-IVD	CE IVD	CE_IVD	CE_IVD	CE_IVD
<b>PLATFORM</b>	ELITe InGenius®	COBAS 4800	COBAS 6800/8800	M2000sp/rt	Alinity m
<b>TAT (min)</b>	2h 30m	96 in 3h 30m, 192 in 5 h	96 in 3h 30m 192 in 5 h	96 in 7h 25 min.	<115 min
<b>Genotypes</b>	group M, group O, group N and main CRF's	Group M , Group O, Group N	Group M , Group O, Group N	Group M , Group O, Group N	Group M , Group O, Group N
<b>Matrix Samples</b>	Plasma EDTA and ACD	EDTA plasma	EDTA plasma	Plasma	Plasma
<b>Sample processing volume</b>	600µL	400uL or 200µL	500 µL or 200 µL	600µL	600µL
<b>Amplicon Region</b>	Integrase region (pol domain)	Gag and LTR regions	Gag and LTR regions	Integrase and LTR	Integrase and LTR
<b>LOD</b>	60 IU/mL plasma 26 copies / mL plasma	400 µL: 14.2 copies/mL 200 µL: 43.9 copies/mL	500 µL: 13.2 copies/mL 200 µL: 35.5 copies/mL	40 copie/mL	10 IU/mL in plasma
<b>Linear Range</b>	60-3,2x10 <sup>8</sup> IU / mL	400 µL: 20 - 10 <sup>7</sup> copies/mL 200 µL: 60 - 10 <sup>7</sup> copies/mL	500 µL: 20 – 10 <sup>7</sup> copies/mL 200 µL: 50 -10 <sup>7</sup> copies/mL	10- 2x10 <sup>9</sup> IU/mL	10 to 2 x10 <sup>7</sup> Copies/mL
<b>Specificity</b>	99,5%	100%	100%	100%	100%





# HIV1 ELITe MGB® Kit

## Competition chart








	ELITechGroup	Cepheid	HOLOGIC	QIAGEN
KIT	HIV1 ELITe MGB® KIT	Xpert® HIV1 Viral Load	Aptima® HIV Quant Assay kit	artus® HIV1 QS-RGQ Kit
IVD	CE-IVD	CE IVD	CE_IVD	CE_IVD
PLATFORM	ELITe InGenius®	GenXpert	Panther System	QIAasymphony® SP/AS and Rotor-Gene® Instruments
TAT (min)	2h 30m	1h 30m	120 in 2.4hrs 335 up to 500 in 8 hrs	96 samples in 9h 15m
Genotypes	group M, group N, group O and main CRF's	group M, group N, group O	group M, group N, group O	group M,
Matrix Samples	Plasma EDTA and ACD	Plasma EDTA	Plasma and Serum	Plasma
Sample processing volume	600µL	1ml	1200µL	1300µL
Amplicon Region	Integrase region (pol domain)	LTR (NC)	Polimerase and LTR gene	LTR
LOD	60 IU/mL in plasma 26 copies / mL in plasma	38 IU/mL in plasma	35 IU/ml in plasma	76,4 IU/ml in plasma
Linear Range	60-3,2x10 <sup>8</sup> IU / mL	40-10 <sup>7</sup> IU/ml	2,0 to 6,70 log copies/ml	31.5-2x10 <sup>7</sup> IU/ml
Specificity	99,5%	98,5%	100%	100%



# HCV ELITe MGB® Kit

## Competition chart

					
KIT	HCV ELITe MGB® KIT	Cobas® HCV Test	Cobas® HCV Test	ALINITY m HCV ASSAY	ALINITY m HCV- ASSAY
IVD	CE-IVD	CE IVD	CE_IVD	CE_IVD	CE_IVD
PLATFORM	ELITe InGenius®	COBAS 4800	COBAS 6800/8800	M2000sp/rt	Alinity m
TAT (min)	2h 30m	96 in 3h 30m, 192 in 5 h	96 in 3h 30m 192 in 5 h		
Genotypes	Genotype 1-6	Genotype 1-6	Genotype 1-6	Genotype 1-6	Genotype 1-6
Matrix Samples	Plasma EDTA and ACD and serum	EDTA plasma and serum	EDTA plasma and serum	Plasma and Serum	Plasma and Serum
Sample processing volume	600µL	400uL or 200µL	500 µL	500ul or 200ul	600ul
Amplicon Region	5' UTR	5' UTR	5' UTR	5' UTR	Dual target 5' UTR
LOD	LoD is 26 IU/mL in plasma and serum	400 µL: 9.2 IU/mL plasma 200 µL: 15.2 IU/mL plasma  400 µL: 7.6 IU/mL serum 200 µL: 15.3 IU/mL serum	500 µL: 12 IU/ml Plasma 500 µL: 13.2 IU/ml serum	500 µL: 12 IU/mL 200 µL: 30 IU/mL	600 µL: 8.46 IU/ml Plasma 600 µL: 7.47 IU/ml serum
Linear Range	26-25x10 <sup>6</sup> IU / mL	400 µL: 15 - 10 <sup>8</sup> copies/mL 200 µL: 25 - 10 <sup>7</sup> copies/mL	500 µL: 15 - 10 <sup>8</sup> copies/mL	12- 10 <sup>8</sup> IU/mL	7 to 2 x10 <sup>8</sup> Copies/mL
Specificity	100%	100%	100%	100%	100%



# HCV ELITe MGB® Kit

## Competition chart








KIT	HCV ELITe MGB® KIT	Xpert® HCV Viral Load	Aptima® HCV Quant Assay kit	artus® HCV QS-RGQ Kit
IVD	CE-IVD	CE IVD	CE_IVD	CE_IVD
PLATFORM	ELITe InGenius®	GenXpert	Panther System	QIAasymphony® SP/AS and Rotor-Gene® Instruments
TAT (min)	2h 30m	1h 30m	120 in 2.4hrs 335 up to 500 in 8 hrs	
Genotypes	Genotype 1-6	Genotype 1-6	Genotype 1-6	Genotype 1-6
Matrix Samples	Plasma EDTA and ACD and serum	Plasma and Serum	Plasma and Serum	Plasma and Serum
Sample processing volume	600µL	1ml	1200µL	1200µL
Amplicon Region	5' UTR		5' UTR	5' UTR
LOD	LoD is 26 IU/mL in plasma and serum	4.9 IU/ml in Plasma 6 IU/ml in serum	4.1 IU/ml in Plasma 13.2 IU/ml in serum	21 IU/ml in plasma
Linear Range	26-25x10 <sup>6</sup> IU / mL	10-10 <sup>8</sup> IU/ml	25-10 <sup>8</sup> IU/ml	35-1,6x 10 <sup>8</sup> IU/ml
Specificity	100%	100%	100%	



# HBV ELITe MGB® Kit

## Competition chart

					
KIT	HBV ELITe MGB® KIT	Cobas® HBV Test	Cobas® HBV Test	Abbott RealTime HBV	ALINITY m HBV ASSAY
IVD	CE-IVD	CE IVD	CE_IVD	CE_IVD	CE_IVD
PLATFORM	ELITe InGenius®	COBAS 4800	COBAS 6800/8800	M2000sp/rt	Alinity m
TAT (min)	2h 30m	96 in 3h 30m, 192 in 5 h	96 in 3h 30m 192 in 5 h		300 in 8h
Genotypes	A-I and RF	A-H	A-H	A-H and I	A-H and I
Matrix Samples	Plasma EDTA and ACD Serum	Plasma and Serum	Plasma and Serum	Plasma EDTA and ACD Serum	Plasma EDTA and ACD Serum
Sample processing volume	200µL	400uL or 200µL	200 µL and 500 µL	200 µL and 500 µL	300 µL
Amplicon Region	Polymerase gene (TP domain)	Pre-Core and Core Regiones	Pre-Core and Core Regiones	Surface Antigen gene	Surface Antigen gene
LOD	LoD is 9 IU/mL in plasma and serum	Plasma: 4.4 IU/mL (400 µL) Plasma: 7.6 IU/mL (200 µL) Serum: 2.8 IU/mL (400 µL) Serum: 5.5 IU/mL (200 µL)	Plasma: 6.6 IU/mL(500 µL) Plasma: 15.5 IU/mL (200 µL)	10 IU/mL (500 µL) 15 IU/mL (200 µL)	LoD is 10 IU/mL in plasma and serum
Linear Range	10-3x10 <sup>8</sup> IU/ml	10- 10 <sup>9</sup> IU/mL	25 IU/mL -10 <sup>9</sup> IU/mL(200 µL) 10 IU/mL -10 <sup>9</sup> IU/mL (500 µL)	10- 10 <sup>9</sup> IU/mL	7- 2x10 <sup>9</sup> IU/mL
Specificity	96,7%	100%	100%	100%	100%



# HBV ELITe MGB® Kit

## Competition chart



	ELITechGroup	Cepheid	HOLOGIC	QIAGEN
KIT	HBV ELITe MGB® KIT	Xpert® HBV Viral Load	Aptima® HBV Quant Assay kit	artus® HBV QS-RGQ Kit
IVD	CE-IVD	CE IVD	CE_IVD	CE_IVD
PLATFORM	ELITe InGenius®	GenXpert	Panther System	QIAasymphony® SP/AS and Rotor-Gene® Instruments
TAT (min)	2h 30m	57m	120 in 2.4hrs 335 up to 500 in 8 hrs	
Genotypes	A-I and RF	A-H	A-H	A-H
Matrix Samples	Plasma EDTA and ACD Serum	Plasma and Serum	Plasma EDTA and ACD Serum	Pre-core region
Sample processing volume	200µL	600µL	700µL	
Amplicon Region	Polymerase gene (TP domain)		Polimerase and surface gene	
LOD	LoD is 9 IU/mL in plasma and serum	Plasma: 3,20 IU/ml Serum: 5,99IU/ml	Plasma: 5.58 IU/ml Serum: 4.29IU/ml	Plasma:10.2IU/ml
Linear Range	10-3x108 IU/ml	10-109 IU/ml	10- 109 IU/mL	31.5-2x107 IU/ml
Specificity	96,7%	100%	100%	






## MKT & Scientific Material





# Customer & MKT Presentation

## Marketing Material



### HOW SHOULD I USE IT?

- Marketing presentation: it contains confidential info. You do not have to share it with customers but keep it as reference for personal purposes.
- Customer presentation: sales tool to be used at customer's site to present BeGenius. It is not confidential, can be shared with customer in not editable format (pdf).

**HOW CAN I HAVE IT?** Downloadable from ELITeBoard and sent as attachment within the launch announcement by e-mail.



## Teaser Marketing Material



**WHAT IS IT?** Tool used to promote the product and to circulate information about it.

**HOW SHOULD I USE IT?** Share it with your customers!

**HOW CAN I HAVE IT?** Downloadable from the Website, ELITeBoard and sent as attachment within the launch announcement by e-mail.

**AVAILABLE STARTING FROM: March 2022**



# Brochure Marketing Material



**WHAT IS IT?** Tool used to promote the product and to circulate information about it.

**HOW SHOULD I USE IT?** Share it with your customers!

**HOW CAN I HAVE IT?** Downloadable from the Website, ELiTeBoard and sent as attachment within the launch announcement by e-mail.

**AVAILABLE STARTING FROM: March 2022**

# Materiale MKT


## Banner web page

**Decades of  
building  
laboratory  
excellence**

**BLOOD BORNE VIRUSES PANEL**

- HIV ELITe MGB® Kit
- HCV ELITe MGB® Kit
- HIV1 ELITe MGB® Kit

- CE-IVD marked
- Quantitative assays
- Ease of use on ELITe InGenius® system
- HIV and Hepatitis patient monitoring affordable to any lab
- Open up your possibilities with our comprehensive solution



[View Details](#)

[For US market, please click here](#)

**SARS-CoV-2 ELITe MGB® Kit**

- CE-IVD marked
- Detects SARS-CoV-2 with High Sensitivity and Specificity
- ELITe InGenius® and all major PCR cyclers
- Detects simultaneously RdRp gene and ORF8 gene
- Qualitative and Quantitative
- In full compliance with the WHO Laboratory Guidelines \*

**OMICRON  
VARIANT  
DETECTED!**



[View details](#)

[For US market, please click here](#)

# Scientific Material

## Poster 31<sup>st</sup> ECCMID 9-12 July 2021

31<sup>st</sup> **ECCMID** Online  
9 – 12 July 2021

**ESCMID** EUROPEAN SOCIETY OF CLINICAL  
MICROBIOLOGY AND INFECTIOUS DISEASES

**HBV ELITe MGB Kit<sup>®</sup> and ELITe InGenius<sup>®</sup>:**  
**a new system for the Quantification of HBV DNA**  
**in plasma and serum samples**  
G. Bovolenta, D. Barberis, C. Bittoto, S. Costa, C. Olivo, G. Stefanuto  
*ELITechGroup Molecular diagnostics*

Poster # 4810

**ELITechGroup**  
EMPOWERING IVD


### BACKGROUND

HBV viral load quantification is necessary to support clinical decisions in starting and manage anti-HBV treatments. The HBV monitoring is mainly performed at laboratories of major hospitals, with a long sample-to-result time and difficulties in reaching the care centers. This can result in delaying responses to clinicians and leaving patients during the follow-up. Integrated, easy-to-use, small-footprint platforms like ELITe InGenius<sup>®</sup> may offer a new tool in HBV monitoring. In this study, we evaluated the analytical and diagnostic performance of the new system HBV ELITe MGB Kit<sup>®</sup> and ELITe InGenius<sup>®</sup> in comparison to the cobas<sup>®</sup> HBV test and cobas<sup>®</sup> 4800/6800 System (Roche Diagnostics). Statistical analysis was performed with MINITAB<sup>®</sup> (SV 19.2020.1).


### MATERIAL & METHODS

The Limit of detection (LoD) was evaluated by Probit analysis on a serial dilution of the 4th WHO International standard for HBV DNA for NAT on ACD-plasma, and confirmed on EDTA plasma and serum according to the CLSI guideline-EP17-A. The secondary reference material Hepatitis B virus Concentrate (ZeptoMetrix) was used in serial dilutions from  $10^5$  to about  $10^4$  IU/mL in EDTA-plasma, to assess the linearity of measurement. The QCMD 2020 Hepatitis B Virus DNA EQA Programme (QCMD Ltd.) was used to assess the system reproducibility. In the performance comparison, 127 HBV negative and 131 positive samples of EDTA-plasma were tested in parallel with HBV ELITe MGB Kit<sup>®</sup> on ELITe InGenius<sup>®</sup> and cobas<sup>®</sup> HBV on cobas<sup>®</sup> 4800/6800 System (Roche Diagnostics). Statistical analysis was performed with MINITAB<sup>®</sup> (SV 19.2020.1).

### RESULTS



- The LoD was equal to 9 IU/mL.



- The linearity of measurement ranged from  $9$  to  $3.18 \times 10^8$  IU/mL.
- The linearity measurement within clinically relevant concentrations was confirmed for the main HBV genotypes (A, B, C, D, E, F, G) with R2 from 0.979 to 0.996 and quantitative results within 50.5 Log IU/mL.




[www.elitechgroup.com](http://www.elitechgroup.com)  
[scientific.dept@elitechgroup.com](mailto:scientific.dept@elitechgroup.com)

- The reproducibility of secondary reference material with titers from 1.7 to 3.8 Log IU/mL was within the expected SD range, from  $\pm 0.13$  to  $\pm 0.23$ .

Sample ID	HBV genotype	Consensus Log IU/ml	SD Log IU/ml	ELITe InGenius Log IU/ml
HBVDNA1015-01	type A	2.823	0.130	2.695
HBVDNA1015-02	type D	2.673	0.148	2.625
HBVDNA1015-03	type D	3.642	0.155	3.579
HBVDNA1015-04	negative	-	-	-
HBVDNA1015-05	type A	1.869	0.229	1.688
HBVDNA1015-06	type A	3.803	0.156	3.781
HBVDNA1015-07	type A	2.848	0.176	2.696
HBVDNA1015-08	type D	1.724	0.227	1.422

- Evaluation over clinical samples showed 97.6% agreement on negative specimens (127) and 100% on positives (131).



- Over 131 plasma samples with titer within the linearity measurement range, regression analysis showed excellent correlation between HBV ELITe MGB Kit<sup>®</sup>, ELITe InGenius<sup>®</sup> and cobas<sup>®</sup> HBV kit, with an intercept equal to 0.085 [95% CI: -0.009 – 0.179], a slope equal to 0.987 [95% CI: 0.959 – 1.015] and R2 equal to 0.974.

### CONCLUSIONS

HBV ELITe MGB Kit<sup>®</sup> and ELITe InGenius<sup>®</sup> system showed optimal sensitivity in detecting HBV DNA genotypes A, B, C, D, E, F, G, H, I and RF accurate quantification of HBV DNA over an extensive viral load range. Such performances and the easiness of use make this system an interesting solution for small monitoring routines or backup of high throughput routine.

### REFERENCES

- S. Velasco et al., The Global Hepatitis B Virus Genotype Distribution Approximated from Available Genotyping Data, Genes, 2018 Oct 23;9(10):493.
- European Association for the Study of the Liver, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, J Hepatol, 2017 Aug;67(2):270-286.
- Terrault N, et al, Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B, AASLD 2018 Hepatitis B Guidance, HEPATOLOGY 2018, VOL. 67, NO. 4, 2018

**EG SOLUTION SHOWED OPTIMAL SENSITIVITY  
AND QUANTIFICATION OF HBV DNA OVER AN  
EXTENSEIVE VIRAL LOAD RANGE**




# Take Home Message



# Take Home Message

**BBV ELITe MGB® Kit in combination with "Genius Way"**



Complete solution for monitoring HIV+ patients (HHV8, Aspergillus, Pneumocystis, HLA B5701)

Indicated for monitoring patients during antiviral therapy

Possibility of eluate recovery for further diagnostic investigations (i.e. drug resistance, NGS, etc)

Optimized management of controls and calibrators

Can be used with different matrices (CFS)

Extension of detected groups and subtypes for HIV (CRF)

Single samples testing without any waste

The extensive menu of tests on a fully automated platform (sample to results)

Tailored for any type of Laboratory testing HIV and hepatitis




# BBV ELITe MGB® Kit

## Ordering Information

Reference Code	Product	Q.ty
RTK602ING	HBV ELITe MGB® Kit	96
RTK600ING	HIV1 ELITe MGB® Kit	96
RTK601ING	HCV ELITe MGB® Kit	96

**THE KIT CONTAINS ALL THE READY-TO-USE REAGENTS,  
STANDARDS AND CONTROLS**

**EVERYTHING YOU NEED IN ONE BOX**





Solutions rather  
than products



[elitechgroup.com](https://elitechgroup.com)

[egspa.marketing@elitechgroup.com](mailto:egspa.marketing@elitechgroup.com)



Molecular Diagnostics

**HBV  
ELITe MGB® Kit**  
Real-Time PCR Assay  
for Hepatitis B  
Monitoring

**MGB**

**IDEAL SOLUTION for all  
small and medium labs**

**EASE OF USE on  
ELITe InGenius® system**

**OPTIMAL SENSITIVITY  
for Hepatitis B  
patient monitoring**

**COMPLETE PANEL  
available in combination  
with HCV and HIV1  
ELITe MGB® Kits**



IVD

In Vitro Diagnostic Medical Device  
Not available in all countries.  
Not available in the United States.



**ELITechGroup**

EMPOWERING IVD

"Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Chronic hepatitis B infection can be treated with oral antiviral agents. Treatment can slow the progression of cirrhosis, reduce incidence of liver cancer and improve long term survival. In 2021 WHO estimated that 12% to 25% of people with chronic hepatitis B infection will require treatment. WHO recommends the use of oral treatments as the most potent drugs to suppress hepatitis B virus. Most people who start hepatitis B treatment must continue it for life".

World Health Organization

**HBV ELITe MGB® Kit** is a quantitative assay detecting the DNA of all known HBV genotypes ( A-I and RF) and provides a new solution in the management of HBV-infected individuals undergoing antiviral therapy.

**HBV ELITe MGB® Kit** used with **ELITe InGenius®** demonstrates optimal sensitivity and quantification of HBV DNA over an extensive viral load range.



## PERFORMANCES

**LoD: 9 IU/ml in serum and plasma samples**

**LoD: 38 copies/ml in serum and plasma samples**

**Specificity: 97,6%**

**Perfect alignment of the result with the most common platforms**

*HBV ELITe MGB® Kit is calibrated with the 4th WHO International Standard, NIBSC.*

## ALL YOU NEED IN ONE BOX

The Kit contains ready-to-use reagents, standards and controls.

## RESULTS IN LESS THAN 3 HOURS

Fast results support better disease management and better patient care



## Ordering information

Reference	Product	Quantity
RTK602ING	<b>HBV ELITe MGB® Kit</b>	96 test

ELITechGroup Molecular Diagnostics, a major innovator in the molecular diagnostic market, offers a comprehensive real-time PCR range of products for diagnosis and monitoring of viral and microbiological infections.



ELITechGroup is certified by DEKRA Certification BV and applies a quality management system in compliance with ISO 9001:2015 and EN ISO 13485:2016

Limited license : Please visit <http://www.elitechgroup.com/corporate/elitemgb-legalnotice> for complete licensing and warranty information. ELITe MGB® is a registered trademark of ELITechGroup. Products not available in the US.



### WORLDWIDE OFFICES

Please contact your sales representative for terms, conditions and product availability in your country.



**Manufacturer:** ELITechGroup S.p.A.

### Administrative and operational site

Corso Svizzera 185  
10149 Turin (TO) - Italy

### Registered office

Corso Italia, 22  
20122 Milan (MI) - Italy

Headquarters	+33 1 41 45 07 10
Australia	+61 1800 815 098
Belgium, Luxembourg	+32 9 282 05 31
Brazil	+55 27 3025 1415
France	+33 4 83 36 10 82
Italy	+39 011 97 61 91

New Zealand	+64 800 555 611
Serbia	+381 11 2467119
The Netherlands	+31 313 430 500
UK	+44 1442 869 320
United States	+1 800 453 2725

**ELITechGroup**  
EMPOWERING IVD  
[www.elitechgroup.com](http://www.elitechgroup.com)  
[info@elitechgroup.com](mailto:info@elitechgroup.com)



## Molecular Diagnostics

# ELITE BeGenius

## TECHNICAL SPECIFICATIONS

Fully automated platform for nucleic acid extraction, PCR set-up, amplification and detection.



### Performance Specifications


Time to first results	2h30 minutes (24 results)
Maximum throughput	72 results/8 hours
Walk-away time	~ 2h30 minutes
Maximum number of tests per run	24 tests
Sample capacity	24 reagent tubes
Reagent capacity	24 reagent tubes; possibility to unload during the run
Reagents	Ready-to-use, barcoded
Operational flexibility	<ul style="list-style-type: none"><li>• Integrated barcode readers for complete traceability of samples and reagents</li><li>• Cooled storage of samples, eluates and reagents to improve their stability on-board and overnight runs.</li><li>• Increase analytical throughput by a thermal block with 24 PCR positions</li><li>• Improved single pipette module to implement high volume dispensing, multidispensing and reduce primary sample dead volume</li><li>• Maximum flexibility in system placement within the laboratory</li><li>• LIS connectivity</li></ul>
Barcode	Samples Barcode: Code 39; Code 128; Interleaved 2 of 5; Codabar; EAN 128 Reagents and Elution Tubes Barcode: DataMatrix

### Physical Dimensions

Width	1,382 mm
Depth	850 mm
Height	1,843 mm
Total weight	440 kg
LCD touch panel	12.1"

## Electrical Specifications

Maximum power input	1050VA (1050W)
Input voltage	100-240V AC +/- 10%
Max current	10.5A/100V or 4.57A/230V
Frequency	50/60Hz
Installation category	Over voltage category: II
Pollution degree	2
Laser device	Class 1



## Channel / Dye      Compatible Dyes      Excitation (nm)      Emission (nm)

1 FAM	FAM, SYBR green, Alexa Fluor 488	470	510
2 AP525	JOE, HEX, VIC	530	555
3 AP559	TAMRA, Alexa Fluor 555, NED	560	590
4 AP593	ROX, Texas Red	590	630
5 AP642	Cy5, Alexa Fluor 647	630	670
6 AP680	Cy5.5, Alexa Fluor 680, Quasar 705	670	710

## Environmental Requirements

Operating temperature	+15 to 30° C
Storage temperature	+5 to 40° C
Transport temperature	-25° to 60° C
Ambient operating humidity	20-80% non-condensing
Maximum altitude	0-2,000 m (6,562 ft)
Non-operating temperature	-20-60° C
Non-operating relative humidity	20-90% non-condensing
Noise level	<70 dBA during 24 PCR amplification
Operation location	For indoor use only
Installation floor	The floor shall be level withstand the load of at least 500kg



ELITechGroup is certified by DEKRA Certification BV and applies a quality management system in compliance with ISO 9001:2015 and EN ISO 13485:2016

Limited license: Please visit <http://www.elitechgroup.com/corporate/elitemgb-legalnotice> for complete licensing and warranty information ELITE MGB® is a registered trademark of ELITechGroup. Products not available in the US



WORLDWIDE OFFICES  
Please contact your sales representative for terms, conditions and product availability in your country.

### Headquarters

Australia  
Belgium, Luxembourg  
Brazil  
France  
Italy

### +331 41 45 07 10

+61 1800 815 098  
+32 92 820 531  
+55 27 3025 1415  
+33 4 83 36 10 82  
+39 011 97 61 91

New Zealand  
Serbia  
The Netherlands  
UK  
United States

+64 0800 555 611  
+381 11 2467119  
+31 313 430 581  
+44 1442 869320  
+1 800 453 2725







Molecular Diagnostics

**MGB**

# HCV ELITe MGB® Kit

Real-Time PCR  
Assay for HCV  
Monitoring

**IDEAL SOLUTION  
for all small and  
medium labs**

**EASE OF USE on  
ELITe InGenius® system**

**OPTIMAL SENSITIVITY  
for HCV patient  
monitoring**

**COMPLETE PANEL in  
combination with HBV  
and HIV1 ELITe MGB® Kits**

CE IVD  
0344

*In Vitro* Diagnostic Medical Device  
Not available in all countries. Not  
available in the United States.



**ELITechGroup**  
EMPOWERING IVD



"Early diagnosis can prevent health problems that may result from infection and prevent transmission of the virus. WHO recommends testing people who may be at increased risk of infection. Quantitative HCV RNA testing is recommended prior to initiating antiviral therapy and at the end of treatment after 12 or 24 weeks. WHO Global goal is to stop HCV by 2030 increasing diagnosis and treatment."

World Health Organization

**HCV ELITe MGB® Kit** is a quantitative assay detecting the RNA of Hepatitis C virus (HCV), genotypes 1, 2, 3, 4, 5 and 6 providing a new solution for the management of HCV- infected individuals undergoing antiviral therapy.

**HCV ELITe MGB® Kit** in combination with **ELITe InGenius®** shows optimal sensitivity and quantification of HCV RNA.



## PERFORMANCES

**LoD: 26 IU/ml in plasma and serum samples**

**LoD: 11 copies/ml in plasma and serum samples**

**Diagnostic Specificity: 100%**

## ALL YOU NEED IN ONE BOX

The Kit contains ready-to-use reagents, standards and controls.

## RESULTS IN LESS THAN 3 HOURS

Fast results support better disease management and better patient care



## Ordering information

Reference	Product	Quantity
RTK601ING	<b>HCV ELITe MGB® Kit</b>	96 test

ELITechGroup Molecular Diagnostics, a major innovator in the molecular diagnostic market, offers a comprehensive real-time PCR range of products for diagnosis and monitoring of viral and microbiological infections.



ELITechGroup is certified by DEKRA Certification BV and applies a quality management system in compliance with ISO 9001:2015 and EN ISO 13485:2016

Limited license : Please visit <http://www.elitechgroup.com/corporate/elitemgb-legalnotice> for complete licensing and warranty information. ELITe MGB® is a registered trademark of ELITechGroup. Products not available in the US.



### WORLDWIDE OFFICES

Please contact your sales representative for terms, conditions and product availability in your country.



**Manufacturer:** ELITechGroup S.p.A.

### Administrative and operational site

Corso Svizzera 185  
10149 Turin (TO) - Italy

### Registered office

Corso Italia, 22  
20122 Milan (MI) - Italy

Headquarters	+33 1 41 45 07 10
Australia	+61 1800 815 098
Belgium, Luxembourg	+32 9 282 05 31
Brazil	+55 27 3025 1415
France	+33 4 83 36 10 82
Italy	+39 011 97 61 91

New Zealand	+64 800 555 611
Serbia	+381 11 2467119
The Netherlands	+31 313 430 500
UK	+44 1442 869 320
United States	+1 800 453 2725

**ELITechGroup**  
EMPOWERING IVD  
[www.elitechgroup.com](http://www.elitechgroup.com)  
[info@elitechgroup.com](mailto:info@elitechgroup.com)